Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., explained in plain language.
Pharmaceutical company manufacturing and developing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New triple therapy takes on pancreatic cancer Results expected Nov 2026 (estimated)
- New antibody drug aims to cut COPD attacks in half Results expected Mar 2027 (estimated)
- New hope for bile duct cancer: experimental drug targets HER2 Results expected May 2027 (estimated)
- New hope for Hard-to-Treat colorectal cancer: targeted drug combo enters human trials Results expected Jun 2027 (estimated)
- New pill TQH3906 tested for tough gut diseases Results expected Jul 2027 (estimated)
-
New hope for Hard-to-Treat colorectal cancer: targeted drug combo enters human trials
Disease control Not yet recruitingThis study tests a new drug called TQB2930, which targets the HER2 protein on cancer cells, combined with standard chemotherapy and possibly another drug (bevacizumab). The goal is to find the safest and most effective dose and see if it shrinks tumors in people with advanced col…
Phase 1/2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: targeted drug TQB2102 enters phase 3 trial
Disease control Not yet recruitingThis Phase 3 trial tests a new drug called TQB2102, which delivers chemotherapy directly to HER2-positive cancer cells, in people with advanced colorectal cancer that has stopped responding to standard treatments. About 142 participants will be randomly assigned to receive either…
Phase 3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC